

A Quantitative Characterization of the Spatial Distribution of Brain Metastases from Breast Cancer and Respective Molecular Subtypes

Saeedeh Mahmoodifar, M.S.,³ Dhiraj J. Pangal, B.S.,¹ Tyler Cardinal, B.S.,¹ David Craig, Ph.D.,⁴ Thomas Simon, Ph.D.,⁴ Ben Yi Tew, Ph.D.,⁴ Wensha Yang, Ph.D.,⁶ Eric Chang, M.D.,⁶ Min Yu, Ph.D.,⁶ Josh Neman, Ph.D.,¹ Jeremy Mason, Ph.D.,⁵ Arthur Toga, Ph.D.,⁶ Bodour Salhia, Ph.D.,⁴ Gabriel Zada, M.D., M.S.,¹ and Paul K. Newton, Ph.D.^{2,*}

¹Department of Neurosurgery Keck School of Medicine of University of Southern California 1300 N. State Street, Suite 3300 Los Angeles, CA 90033

²Department of Aerospace and Mechanical Engineering, Mathematics and The Ellison Institute for Transformative Medicine of USC

Viterbi School of Engineering, University of Southern California 854 Downey Way Los Angeles, CA 90089

³Department of Physics Astronomy University of Southern California Los Angeles, CA 90089

⁴Department of Translational Genomics Keck School of Medicine of University of Southern California 1450 Biggy Street Los Angeles, California, 90033

⁵Convergent Science Institute in Cancer, Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, CA 90089

Catherine Joseph Aresty Department of Urology, Institute of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033

⁶Keck School of Medicine of University of Southern California, Los Angeles, California, 90033

*newton@usc.edu

Disclosure: The authors have no conflicts of interest to disclose.

Key words: Brain metastases; Breast cancer; Principal components; Mutual information

Abstract word count: 234, **Text word count:** 4017, **Number of references:** 29, **Number of tables/figures:** 8, **Number of videos:** 0

1. Abstract

Brain metastases (BM) remain a significant cause of morbidity and mortality in breast cancer (BC) patients. Specific factors promoting the process of BM and predilection for selected neuro-anatomical regions remain unknown, yet may have major implications for prevention or treatment. Anatomical spatial distributions of BM from BC suggest a predominance of metastases in the hindbrain and cerebellum. Systematic approaches to quantifying BM location or location-based analyses based on molecular subtypes, however, remain largely unavailable. We analyzed stereotactic Cartesian coordinates derived from 134 patients undergoing gamma-knife radiosurgery (GKRS) for treatment of 407 breast cancer BMs to quantitatively study BM spatial distribution along principal component axes and by intrinsic molecular subtype (ER,PR,Herceptin). We corroborated that BC BMs show a consistent propensity to arise posteriorly and caudally, and that Her2+ tumors are relatively more likely to arise medially rather than laterally. To compare the distributions among varying BC molecular subtypes, we used the notion of mutual information, which revealed that the ER-PR-Her2+ and ER-PR-Her2- subtypes showed the smallest amount of mutual information and were most molecularly distinct. Using kernel density estimators, we found a propensity for triple negative BC to arise in more superiorly or cranially situated BMs. BM location maps according to vascular and anatomical distributions using cartesian coordinates to aid in systematic classification of tumor locations were additionally developed. Further characterization of these patterns may have major impacts on treatment or management of cancer patients.

48 **Significance:** The quantitative spatial distribution of breast cancer metastases to the brain, and the
49 effects of breast cancer molecular subtype on distribution frequencies remain poorly understood.
50 We present a novel and shareable workflow for characterizing and comparing spatial distributions
51 of BM which may aid in identifying therapeutic or diagnostic targets and interactions with the
52 tumor microenvironment.

53 **2. Introduction**

54 In patients with breast cancer (BC), brain metastases (BM) are a significant source of morbidity
55 and mortality, and average interval between diagnosis of BM and death remains under two years [6].
56 Despite significant advances in systemic treatment of primary breast cancer, treatment for BM
57 remains mostly confined to surgical resection, stereotactic radiosurgery, and less commonly
58 whole brain radiation therapy.

59 BM from BC have been reported to show preferential spatial metastatic patterns within the brain,
60 with a predominance of lesions arising in the posterior circulation and cerebellum [1–3]. While
61 the spatial distributions for BM have been described in a qualitative fashion (e.g. located
62 in cerebellum), there have been minimal efforts to systematically and quantitatively analyze
63 spatial distributions of BM. In addition, the influence of molecular subtype in topographic BM
64 distribution remains largely unknown.

65 There is relevant clinical and potential therapeutic motivation for understanding the spatial
66 distribution of BM, specifically according to cancer origin and molecular subtype. There has been
67 growing interest in the relationship between the tumor microenvironment (TME), surrounding
68 both tumor and normal brain parenchyma, and the development of BM, which is referred to as the
69 ‘seed-and-soil’ hypothesis [4–6]. Recent studies have characterized a need for priming a metastatic
70 niche prior to BM colonization and tumorigenesis [7–9]. A more thorough understanding of the
71 patterns of spatial distribution of BM and the influence of TME on tumorigenesis may provide
72 potential targets for diagnosis or treatment of BM.

73 Gamma Knife Radiosurgery (GKRS) is a highly targeted form of stereotactic radiosurgery and is a
74 first line therapy for many BM, particularly those in which surgical resection is unfavorable [10, 11].
75 The use of stereotactic frames and precise, predetermined locations in three-dimensional space
76 allow for Cartesian coordinates of tumors to be recorded and studied (Figure 1) using spatial
77 modeling techniques. We describe a novel computational approach for characterizing and
78 comparing the spatial distribution of BM arising from BC, using objective tumor location data
79 from patients undergoing GKRS. Tumor locations were analyzed using kernel density plots and
80 principal components analyses (data-based coordinates), and further characterized and compared
81 according to BC molecular subtype. We compared two distributions using the metric of mutual
82 information which is a (nonlinear) measure of the mutual dependence between two random
83 variables [12]. A standard interpretation of mutual information is that it quantifies the amount
84 of information obtained about one random variable by observing the other, thus low values
85 indicate that the distributions are more distinct (independent) than distributions with higher
86 values. While this study introduces new tools for quantifying spatial distributions of BM using
87 large comprehensive data sets collected over a twenty-year period, it also paves the way for
88 further analyses with larger, prospective multi-center studies across a variety of cancers and
89 molecular subtypes to further elucidate natural distribution patterns of BM and their importance
90 for improving cancer treatment.

91 **3. Methods**

92 *3.1. Radiosurgery Setup and Patient Selection*

93 Gamma Knife radiosurgery (GKRS) is a commonly used frontline treatment modality in which a
94 stereotactic frame (Leksell coordinate frame, see Figure 1) is used in conjunction with cobalt

95 radiation sources to deliver precise doses of radiotherapy to highly accurate locations in three-
96 dimensional space corresponding to contoured BM on MRI (Figure 2). Predetermined target
97 coordinates are utilized, and patients are fixed to the stereotactic Leksell coordinate frame as
98 depicted in Figure 1. As a result, Cartesian coordinates (X,Y,Z) in 3D space of each BM central
99 location are obtained and recorded.

100 All patients undergoing GKRS at The Keck Hospital of the University of Southern California
101 (USC) between the years 1995-2015 for the treatment of BM were reviewed and analyzed
102 following approval from the local USC IRB. Those with primary BC were identified, and
103 retrospective chart review was conducted to determine molecular subtype (ER, PR and Her2/Neu
104 [HER2]). Samples were divided into 6 major subtypes based on HER2, ER and PR receptor
105 status. Subtype information was available in 134 patients comprising a total 407 intracranial
106 metastases. Clinical data gathered included: sex, age at diagnosis of primary cancer, age at
107 diagnosis of BM, ER status, PR status and Her2/Neu status. To avoid potential confounders with
108 prior radiation therapy, only patients with their first radiation treatment were included and those
109 with prior radiation or radiosurgery were excluded. Multiple metastases from individual patients
110 (at one treatment) were included. See data summary in Table ??.

111 GKRS planning and treatment were performed by a multidisciplinary team including a neurosur-
112 geon, radiation oncologist, and medical physicist. Tumor locations were recorded as (X,Y,Z)
113 values on a Cartesian plane, corresponding to the Leksell coordinate frame axes and recorded
114 using GammaPlan™ software (Elekta corporation). In addition, specific clinical locations (e.g.
115 Left frontal lobe) as well as tumor volume, number of treatments, vascular distribution, and
116 radiation dose were recorded.

117 3.2. Principal component analysis (PCA) and mutual information (MI)

118 The principal component (PC) coordinates are a data-based orthogonal coordinate system
119 designed to bring out the directions of maximal spread of the data and used in many settings in
120 which patterns are sought from large data sets [13]. The PC coordinates are linear combinations
121 of the three (X,Y,Z) physical coordinates, with mean at the origin, mutually orthogonal (so they
122 span the same space as X-Y-Z), and such that PC1 lies in the direction of maximal spread, PC2 is
123 orthogonal to PC1 and is in the next most likely direction of spread, while the PC3 direction
124 is orthogonal to both, with the least direction of spread. Since the method of calculating the
125 PC coordinates is standard, we refer the interested readers to Kirby [13] for theoretical details.
126 We use scikit-learn Python package [14] for our data analysis. To compare two distributions
127 associated with different molecular subtypes, we use the notion of mutual information (MI) [12]
128 (relative entropy) which quantifies nonlinear mutual dependence between two random variables.
129 If the MI is zero between two random variables, they are deemed to be completely independent
130 and unrelated, which implies that using observations drawn from one has no value in predicting
131 sequences generated by the other. The formula we use to estimate MI is [15]:

$$MI(X;Y) = \frac{1}{n} \sum_{i=1}^n \log\left[\frac{p_{XY}(x_i, y_i)}{p_X(x_i)p_Y(y_i)}\right] \quad (1)$$

132 where $p_{XY}(x_i, y_i)$ is the estimated joint PDF, and $p_X(x_i)$ and $p_Y(y_i)$ are the estimated marginal
133 PDF's at (x_i, y_i) . The larger the MI value, the more the distributions are correlated, i.e. one
134 distribution carries a high amount of information about the other. A very useful discussion and
135 application of MI can be found in reference [16].

136 3.3. Kernel density estimators and bootstrap method

137 Kernel density estimators offer a useful tool to convert a discrete multivariate data set into
138 smoothed, multivariate distributions to extract information and patterns associated with the

139 probability distribution function associated with data [17]. Color gradient bars and contours are
140 then used to identify ‘hot spot’ regions of highest density (probability), and regions of lowest
141 density (probability). In principle, the computed MI does not depend on the size of the data
142 sets being compared, although well known issues can arise from smaller data sets [15, 16]. For
143 these reasons, to overcome the issue associated with small and unequal sizes of data sets for
144 different molecular subtypes, we use a bootstrap (resampling) method [18], starting from the
145 smoothed multivariate distributions obtained for each subtype (from the original data sets) to
146 generate sample data of 1000 points and then calculate the MI values (see Table S2) for those
147 points between each pair of subtypes. We carry out this re-sampling step and MI calculation step
148 1000 times, and obtain sample means and standard deviations for the MI for each pair using the
149 enlarged data sets generated from sampling from the distributions generated from the original
150 data sets.

151 4. Results

152 The data set is compiled in Table ?? which shows the number of BM for each of the molecular
153 subgroups, as well as details associated with Figures 2-8, S1, S2. Figure 2 shows the entire
154 data set of brain metastases (Figure 2 A,B,C) for our cohort of breast cancer patients, in the
155 sagittal, axial, and coronal planes. These same views are shown in Figure 2 D,E,F as kernel
156 density plots depicting the density distributions associated with the data. The darkest enclosed
157 regions of the kernel density plots nicely depict the highest density regions (‘hotspots’), which
158 generally cluster towards the midline (coronal, axial view), posteriorly and caudally (sagittal).
159 Figure S9 shows the same data broken down according to the molecular subtype (along each
160 column): ER-PR-Her2+; ER+PR+Her2-; ER-PR-Her2-(TNBC); ER+PR+Her2+ (TPBC). The
161 red dot marks the mean position. The corresponding kernel density plots for the molecular
162 subgroups are shown in Figure 3 . The sagittal view across all subtypes (Figure 3, Row 1)
163 demonstrates clear maximal clustering in the posterior, caudal region of brain; however TNBC
164 appears to visually cluster superiorly/cranially compared to the other breast cancer subtypes. We
165 next focused on elucidating differences in topographic patterns associated with the molecular
166 subgroups by using the principal component axis coordinates [13]. The principal component
167 coordinates are a rotated orthogonal coordinate system centered at the mean of the data that
168 are optimally designed to highlight the largest spread direction (PC1). In Figure 4 we show
169 the relationship between the principal component coordinates (PC1-PC2-PC3) and the physical
170 cartesian coordinates (X-Y-Z). Figure 4 A shows PC1-PC2-PC3 in the X-Y-Z space, while
171 Figures 4 B,C,D shows each of the two-dimensional projections. From Figure 4 B we can see
172 that PC1 lies predominantly in the anterior-posterior (Y), although with other components as
173 well (Figure 4 C,D). The precise linear relationship between the two coordinate systems is given by:

$$\begin{aligned} 174 \quad PC1 &= -0.0486(1, 0, 0) + 0.7672(0, 1, 0) + 0.6396(0, 0, 1) \\ PC2 &= -0.6140(1, 0, 0) \sim 0.5280(0, 1, 0) + 0.5867(0, 0, 1) \\ PC3 &= -0.7878(1, 0, 0) + 0.3642(0, 1, 0) \sim 0.4968(0, 0, 1) \end{aligned} \quad (2)$$

175 In Figure S10 we compare the spatial distributions in the original X-Y-Z coordinates and the
176 principal component axes (PC1-PC2-PC3) from the full data set for the six molecular subtypes:
177 Her2+, ER+, PR+, PR-, Her2-, ER- separately. In each plot, the yellow horizontal bar marks the
178 mean, while the white dot marks the median. The colors mark the molecular subtype, as shown in
179 Figure S10 A which most clearly shows the divergence along the PC1 axis which is the direction
180 of maximal spread. To understand the advantages of using the principal component coordinates
181 over the cartesian coordinates, in Figure S10 A it is clear that the median lies below the mean
182 (i.e. is shifted back with respect to the mean), with the three negative subtypes shifted further
183 back than the three positive ones. Comparing this with Figure S10 E (spread along Y-axis), the

184 pattern is not nearly as clear. For each pair of violin plots (distributions), we calculate the mutual
185 information score (MI) along with standard deviations using the bootstrap method described
186 earlier. Lower MI score indicates less mutual dependence between the compared distributions,
187 higher MI score indicates more mutual dependence. Figure 5 A-F shows the same as Figure
188 S10, but using the molecular subgroupings: TPBC; ER+PR+Her2-;ER-PR-Her2+; TNBC. The
189 divergence between the mean and the median is largest in the triple negative grouping, shown
190 most clearly in Figure 5 A along the PC1 axis. An ordered listing of all of the MI scores for
191 each pair of molecular subtypes is shown in Table S2 and presented visually for the individual
192 subtypes in Figure 8 as a heat map. The ordering in Table S2 goes from smallest to largest along
193 the PC1 axis (first column), with all other axes also shown. In Table S2 and Figure 5 A we
194 draw attention to the fact that the pair with the smallest MI value (8.966 +/- 3.394) is between
195 ER-PR-Her2+ and ER-PR-Her2-, i.e. those two groupings are the most molecularly distinct.
196 The two groups with the largest MI value (14.808 +/- 3.589) is between ER+PR+Her2+ and
197 ER+PR+Her2-, i.e. those two groupings are the most molecularly similar (more important than
198 the nominal values of these MI scores are the differences between them).
199 Figures 6 and 7 show the differences between anterior vs. posterior and lateral vs. medial
200 lesions from the sagittal, axial, and coronal views (Figure 6) and according to molecular subtype
201 groupings. While Figures 7 A-D show the Count (number of metastatic lesions), Figure 7 E-H
202 shows the proportion in each of the regions. It is clear that from Figure 6, the majority of lesions
203 are located in the posterior circulation or watershed areas, and BMBC are relatively rare in the
204 anterior circulation. Figures 7 G,H demonstrate the differences in medial vs lateral distribution
205 of these tumors. It is clear from Figure 7 G that midline tumors are most common across
206 all molecular subtypes. In addition, it appears that Her2+ tumors have the highest proportion
207 of medial metastases, and more rarely metastasize laterally. This is consistent (Figure 7 H)
208 within the molecular subgroups as well, with ER+PR+Her2+ tumors having similar categorical
209 distributions to ER-PR-Her2+ tumors but significantly different than TNBC or ER+PR+Her2-
210 tumors.

211 5. Discussion

212 Accurate quantitative characterization and analysis of BM distributions for primary breast cancer,
213 broken down according to molecular subtypes, is an important step in the direction of highly
214 personalized oncologic therapy and an understanding of the dynamics between BM subtypes and
215 the TME that promote or inhibit the formation of metastasis. To further classify the relationship
216 between a tumor and the microenvironment in which growth is facilitated or the genetic influences
217 which allow for tumor growth in a particular environment, the specific location of tumor foci
218 must be accurately and quantitatively analyzed. Although collecting, quantifying, and processing
219 this information from large multicenter datasets is ongoing, our intention was to develop and
220 share a practical and novel workflow for objective and data-driven analysis of BM distribution,
221 along with useful quantitative techniques that are broadly applicable to other cancer types, larger
222 data sets, and a wide range of centers whom intend to investigate similar relationships. While
223 the seed-and-soil hypothesis has been an accepted overarching framework for over 100 years,
224 detailed information about the spatial distributions of metastases in sensitive organs and broken
225 down by tumor types and molecular subtypes is lacking [12]. In this study, we describe current
226 methods for quantifying the spatial distribution of brain metastases, describe the utility of GKRS
227 coordinates to facilitate this quantification, and discuss future applications and possibilities using
228 widespread coordinate mapping and analysis.

229 In preliminary analyses, triple negative breast cancers or TNBC (i.e. estrogen receptor negative,
230 progesterone receptor negative) with varying her2 status were the most spatially distinct. In
231 contrast, hormone receptor positive tumors with differing her2 status were the most similar. This
232 suggests that hormone receptor status may disproportionately influence the spatial distribution of

233 metastases. One hypothesis is that hormone receptor status, when ‘silent’, then allows her2 status
234 to drive spatial distribution of BM. Conversely, when ‘activated’ (e.g. progesterone positive
235 and estrogen positive), differences in her2 status may be more muted, at least in the context of
236 spatial distribution. Clinically, luminal breast cancer (hormone receptor positive, Her2 negative)
237 demonstrates distinct responses to therapies, and have a slower rate of growth and more positive
238 outcomes. In addition, there is a relationship between TNBC, Her2-negative/hormone receptor
239 positive tumors and mutations in the genes BRCA1 and BRCA2. These additional genetic markers
240 may influence the spatial makeup of these subtypes and may validate the mutual information
241 scores determined between these subtypes. Furthermore, hormone receptor positive tumors,
242 regardless of their Her2 status, tend to portend the best clinical outcomes for patients. While
243 this phenomenon is currently largely driven by therapeutic targets afforded by hormone receptor
244 positivity, there may be additional genetic drivers which also influence spatial distribution.
245 While several groups have aimed to categorize tumor location by subtype using MRIs, these studies
246 are generally pilot studies and relatively small in sample size [19–22]. The non-granular level of
247 anatomical precision from MRI studies (e.g. describing tumor location qualitatively as ‘frontal
248 lobe’) often prevents further downstream analysis of these tumor distributions using advanced
249 mathematical and computational means. This precision becomes important when discussing
250 embryologic, signal-based and/or genetic and epigenetic influences in tumor development;
251 discriminating between the midline frontal lobe and more lateral aspects is meaningful as these
252 regions have different vascular distributions, functions and are likely embryologically driven
253 by different mechanisms, despite being in the same lobe [22]. FOX genes, for instance, are
254 theorized to drive midline brain development and Sonic Hedgehog (SHH) has been shown to
255 drive cerebellar development [23–25]. The process of anatomical mapping of brain metastases
256 when performed via MRI is also sensitive to variations in institutional MRI sequence protocol,
257 and can influence the spatial mapping of tumors, as shown by a study by Kyeong et al [25] and
258 Izustsu et al [26] who mapped genetic subtypes of breast cancer with differing MRI sequences
259 and obtained conflicting results [25, 26]. Lastly, MRI reading requires a trained neuro-radiologist
260 and is time consuming and tedious, preventing its widespread adoption. While advancements in
261 machine learning and computer vision may allow for precise anatomical landmark distinction at
262 scale, these techniques are not widespread [27].

263 Analysis using GKRS is a promising alternative to qualitative anatomical location analysis for a
264 variety of reasons. GKRS Leksell coordinates are already collected at the time of radiosurgery
265 and utilized in routine clinical care, allowing for ease of implementation. They are specific
266 to each patient and each tumor and provide accurate, three-dimensional coordinates of tumor
267 centroids. Finally, GKRS data are easily scalable and standardizable across institutions for
268 future data collection and does not require manual annotation by skilled professionals, and can
269 be analyzed in an objective and quantitative fashion rather than using categorical descriptors,
270 thereby increasing internal validity of the analyses.

271 By transforming the data from the original Leksell anatomical coordinates to the principal
272 coordinate axes, we are using an optimal data-derived coordinate system that highlights the axis
273 along which there is the largest spread (PC1), the second largest spread (PC2), and the least spread
274 (PC3) of the data. What we lose in this linear transformation is an easily interpretable anatomical
275 frame, but we gain the ability to quantify what would otherwise be very subtle differences among
276 molecular subgroups. We have retained the original anatomical frame, however, to depict the
277 kernel density plots showing the clustering regions along the 3 two-dimensional projections, in
278 order to more easily discern the physical locations in the brain where the clusters occur and to
279 correlate this with blood flow patterns.

280 We further demonstrate that the results obtained by the GKRS coordinate spatial distribution
281 system are accurate and can elucidate meaningful differences in molecular subtype distribution
282 patterns. It has been well described that breast cancer preferentially metastasizes to the cerebellum;

283 KDE plots from GKRS data demonstrate the preference for the posterior circulation and below the
284 central cranio-caudal axis, consistent with a cerebellar distribution [1, 21]. Izutsu et al [26] found
285 that in their cohort of 67 patients with 437 tumors, Her2 positivity was associated with metastases
286 in the putamen and thalamus and less frequently in the cerebellum [26]. Figure 7 corroborates
287 these findings, wherein Her2+ tumors appear to be preferentially distributed on the midline
288 (thalamus and putamen are midline structures). Kyeong et al [25] found that TNBC was evenly
289 distributed in the brain, which is supported by Figure 7 F, where TNBC appears to have a
290 relatively uniform distribution between anterior, posterior and watershed areas of circulation [25].
291 It is important to note that our study did not corroborate all of the findings within the literature-
292 for example Kyeong et al [25] contradicted the findings by Izutsu et al [26] (and our analysis) and
293 found BM from Her2 positive and luminal type tumors more common in the cerebellum and
294 occipital lobe. These inconsistencies (and differences in sequence methods) highlight the need
295 for high quality, standardized data collection and analysis methods. Using mutual information,
296 data on subtype similarity may be explored: for instance, TPBC and hormone negative BC
297 (TNBC, ER-PR-Her2+) had two of the most divergent patterns of distribution. This supports
298 known characterization of BC, where hormone receptor positivity portends significantly improved
299 outcomes [28]. Further characterization of and groupings of subtypes with higher MI coefficients
300 (higher similarity) should also be explored (with larger data sets), such as between ER+PR+Her2+
301 tumors and ER+PR+Her2- tumors; it may be that the clustering of these tumors are both relatively
302 non-preferential, hence they have high MI coefficients, however there may be underlying factors
303 related to tumor microenvironment or other genes which may drive tumorigenesis in similar
304 locations. Subsequent translational/animal models which attempt to categorize growth of tumors
305 based on their location should prioritize investigating tumor subtypes with the most convergent
306 and divergent MI indices.

307 *5.1. Opportunities for Advancement in Diagnosis and Treatment*

308 Neurotransmitters (e.g. gamma-aminobutyric acid (GABA), glutamate, dopamine, etc) are the
309 biochemical backbone for synaptic signaling, but are also utilized for other cellular functions.
310 These neurotransmitters are present in varying concentrations in different regions; for example,
311 GABA-ergic communication is predominant in cerebellum. This difference is also highlighted
312 by blood-flow; and it is speculated that BM have a predominance in the cerebellum due to the
313 difference in blood flow to those regions, however it is unknown why this affect has a nonuniform
314 impact across primary cancers and subtypes. Understanding the spatial distribution of BM based
315 on molecular subtype may further characterize tumor ability to adapt to regional microenviron-
316 ments based on these neurotransmitter distributions, and may promote BM progression [3, 10, 29].
317 There is a need for large, multi-center studies which utilize standardized data collection criteria to
318 accurately map our brain metastases to avoid inaccuracies as previously mentioned, and enhance
319 generalizability and external validity of this work. In addition, the current advantage of MRI
320 mapping vs GKRS is the ability to develop a 1-1 anatomic map. Accordingly, efforts should
321 be made to create a Leksell-Anatomic mapping, wherein specific X,Y,Z coordinates map to
322 a specific location on a standardized cartesian plane. These mapping classifications must be
323 corroborated with in-vitro and animal models, demonstrating the ability to seed tumor more
324 readily in certain areas of the brain, or identify DNA/RNA lineages specific to tumor locations.
325 Finally, this data must be correlated with clinical factors (e.g. time to diagnosis, overall survival,
326 etc.) which can allow for the development of clinical decision trees. Groups have postulated that
327 the accurate classification of subtypes and correlation with high-risk subgroups might warrant
328 increased surveillance in the period following cancer diagnosis but before BM diagnosis, or even
329 prophylactic, low dose radiation to regions of the brain with high susceptibility [26]. These
330 clinical implementations remain distant, however the systematic, quantifiable mapping of BM
331 distributions is an important first step in personalized oncologic care for the patient with BMBC.

332 5.2. Limitations

333 There are limitations to the current study. While stereotactic headsets are standardized in their size,
334 they are fit to a patient's specific head size which may introduce variation in coordinate recordings.
335 Studied across a cohort of hundreds or thousands of patients, however, these individual cranial-
336 frame variations are likely to normalize and not preclude meaningful statistical comparison.
337 Secondly, the anatomical distributions demonstrated (anterior/posterior, medial/lateral) are
338 Cartesian-derived and may have a limited degree of inaccuracy, although GKRS accuracy has
339 been reported to be on the order of 1mm. The data itself introduces a level of systematic bias as
340 it only accounts for patients who had GKRS for treatment of BM, and not patients who elect
341 not to undergo GKRS, those who undergo whole brain radiation, or have undiagnosed BMBC.
342 Furthermore, correlation with MRI endpoints would significantly strengthen this work. However,
343 advanced imaging studies which may allow us to make more definitive claims regarding the
344 tumor-tumor microenvironment specific to anatomic endpoints (e.g. MR angiograms, perfusion
345 MRI, tractography, etc.) were not performed systematically across any significant subset of
346 patients. Lastly, given that individual cancers themselves have differential distribution patterns,
347 by definition, variance within cancers will be far more subtle. Accordingly, our samples may be
348 significantly underpowered to detect meaningful difference in cancer subtype distribution, which
349 is why we employ the bootstrap/re-sampling method. Scaling the analysis described using the
350 current workflow to thousands of BMK patients from multi-center consortia will increase power
351 and allow more meaningful and granular comparison of cancer and molecular BM subtypes.

352 6. Conclusion

353 We demonstrate a novel, objective, data-based methodology for classifying and analyzing the
354 spatial distribution of brain metastases by breast cancer molecular subtypes using stereotactic
355 coordinates, principal component coordinates (PC), and kernel density estimators (KDE) to
356 highlight clustering regions in the brain. We then compare distributions associated with dif-
357 ferent molecular subtypes using the mutual information (MI) metric, which is a widely used
358 bioinformatic metric [15, 16], but to our knowledge has not been used in the current context.
359 This systematic, quantitative method for classifying BM distribution is easy to scale, accurate,
360 and a meaningful step forward towards understanding the relationship between BM tumor
361 microenvironment and tumorigenesis. Her2+ vs. Her2- cancers may show differential patterns
362 based on this pilot study data and novel methodology.

363
364 **Acknowledgments:** Partial funding through the USC Norris Comprehensive Cancer Cen-
365 ter's Multi-Level Cancer Risk Prediction Models pilot project award, 'Molecular, Clinical
366 and Neuro-imaging Determinants of Spatiotemporal Pathogenesis of Cancer-Specific Brain
367 Metastases: Data Analysis and Longitudinal Modeling' (12/01/2020-11/30/2021) is gratefully
368 acknowledged.

369 References

- 370 1. T. Schroeder, P. Bittrich, J. Kuhne, C. Noebel, H. Leischner, J. Fiehler, J. Schroeder, G. Schoen, and S. Gellifßen,
371 "Mapping distribution of brain metastases: does the primary tumor matter?" *J. Neuro-oncology* **147**, 229–235 (2020).
- 372 2. C. C. Quattrocchi, Y. Errante, C. Gaudino, C. A. Mallio, A. Giona, D. Santini, G. Tonini, and B. B. Zobel, "Spatial
373 brain distribution of intra-axial metastatic lesions in breast and lung cancer patients," *J. neuro-oncology* **110**, 79–87
374 (2012).
- 375 3. J. Neman, M. Franklin, Z. Madaj, K. Deshpande, T. J. Triche, G. Sadlik, J. D. Carmichael, E. Chang, C. Yu, B. A.
376 Strickland *et al.*, "Use of predictive spatial modeling to reveal that primary cancers have distinct central nervous
377 system topography patterns of brain metastasis," *J. Neurosurg.* **1**, 1–9 (2021).
- 378 4. I. J. Fidler, S. Yano, R.-d. Zhang, T. Fujimaki, and C. D. Bucana, "The seed and soil hypothesis: vascularisation and
379 brain metastases," *The lancet oncology* **3**, 53–57 (2002).
- 380 5. J. Ma, C. C. Chen, and M. Li, "Macrophages/microglia in the glioblastoma tumor microenvironment," *Int. journal*
381 *molecular sciences* **22**, 5775 (2021).

- 382 6. Q. Liu, H. Zhang, X. Jiang, C. Qian, Z. Liu, and D. Luo, "Factors involved in cancer metastasis: a better understanding
383 to "seed and soil" hypothesis," *Mol. cancer* **16**, 1–19 (2017).
- 384 7. C. Choy, K. I. Ansari, J. Neman, S. Hsu, M. J. Duenas, H. Li, N. Vaidehi, and R. Jandial, "Cooperation of neurotrophin
385 receptor *trkb* and *her2* in breast cancer cells facilitates brain metastases," *Breast Cancer Res.* **19**, 1–11 (2017).
- 386 8. N. Priego, L. Zhu, C. Monteiro, M. Mulders, D. Wasilewski, W. Bindeman, L. Doglio, L. Martínez, E. Martínez-Saez,
387 D. Megías *et al.*, "Author correction: Stat3 labels a subpopulation of reactive astrocytes required for brain metastasis."
388 *Nat. Medicine* **24**, 1481–1481 (2018).
- 389 9. L. Zhang, S. Zhang, J. Yao, F. J. Lowery, Q. Zhang, W.-C. Huang, P. Li, M. Li, X. Wang, C. Zhang *et al.*,
390 "Microenvironment-induced *pten* loss by exosomal *microrna* primes brain metastasis outgrowth," *Nature* **527**,
391 100–104 (2015).
- 392 10. F. Gagliardi, P. De Domenico, S. Snider, F. Roncelli, E. Pompeo, L. R. Barzaghi, A. Bulotta, V. Gregorc, C. Lazzari,
393 S. Cascinu *et al.*, "Role of stereotactic radiosurgery for the treatment of brain metastasis in the era of immunotherapy:
394 A systematic review on current evidences and predicting factors," *Critical Rev. Oncol.* **165**, 103431 (2021).
- 395 11. J. I. Bisson, N. P. Roberts, M. Andrew, R. Cooper, and C. Lewis, "Psychological therapies for chronic post-traumatic
396 stress disorder (ptsd) in adults," *Cochrane database systematic reviews* (2013).
- 397 12. T. Cover and J. Thomas, "Joint entropy and conditional entropy," *Elem. Inf. Theory*, 2nd ed.; John Wiley & Sons:
398 Hoboken, NJ, USA p. 16 (2006).
- 399 13. M. Kirby, *Geometric data analysis: an empirical approach to dimensionality reduction and the study of patterns*,
400 vol. 31 (Wiley New York, 2001).
- 401 14. F. Pedregosa, G. Varoquaux, A. Gramfort, V. Michel, B. Thirion, O. Grisel, M. Blondel, P. Prettenhofer, R. Weiss,
402 V. Dubourg *et al.*, "Scikit-learn: Machine learning in python," *J. machine Learn. research* **12**, 2825–2830 (2011).
- 403 15. S. Khan, S. Bandyopadhyay, A. R. Ganguly, S. Saigal, D. J. Erickson III, V. Protopopescu, and G. Ostrouchov,
404 "Relative performance of mutual information estimation methods for quantifying the dependence among short and
405 noisy data," *Phys. Rev. E* **76**, 026209 (2007).
- 406 16. R. Steuer, J. Kurths, C. O. Daub, J. Weise, and J. Selbig, "The mutual information: detecting and evaluating
407 dependencies between variables," *Bioinformatics* **18**, S231–S240 (2002).
- 408 17. D. W. Scott, *Multivariate density estimation: theory, practice, and visualization* (John Wiley & Sons, 2015).
- 409 18. B. Efron, "The bootstrap and modern statistics," *J. Am. Stat. Assoc.* **95**, 1293–1296 (2000).
- 410 19. T. Cardinal, D. Pangal, B. A. Strickland, P. Newton, S. Mahmoodifar, J. Mason, D. Craig, T. Simon, B. Y. Tew, M. Yu
411 *et al.*, "Anatomical and topographical variations in the distribution of brain metastases based on primary cancer
412 origin and molecular subtypes: A systematic review," *Neuro-Oncology Adv.* **4**, vdab170 (2022).
- 413 20. C. C. Quattrocchi, Y. Errante, C. A. Mallio, D. Santini, G. Tonini, and B. B. Zobel, "Brain metastatic volume and
414 white matter lesions in advanced cancer patients," *J. neuro-oncology* **113**, 451–458 (2013).
- 415 21. K. Hengel, G. Sidhu, J. Choi, J. Weedon, E. Nwokedi, C. A. Axiotis, X. Song, and A. S. Braverman, "Attributes of
416 brain metastases from breast and lung cancer," *Int. journal clinical oncology* **18**, 396–401 (2013).
- 417 22. S. Brandner, "Molecular diagnostics of adult gliomas in neuropathological practice," *Acta Medica Acad.* **50**, 29–46
418 (2021).
- 419 23. H. Kreft and W. Jetz, "Global patterns and determinants of vascular plant diversity," *Proc. Natl. Acad. Sci.* **104**,
420 5925–5930 (2007).
- 421 24. F. Memi, N. Zecevic, and N. Radonjić, "Multiple roles of sonic hedgehog in the developing human cortex are
422 suggested by its widespread distribution," *Brain Struct. Funct.* **223**, 2361–2375 (2018).
- 423 25. S. Kyeong, Y. J. Cha, S. G. Ahn, S. H. Suh, E. J. Son, and S. J. Ahn, "Subtypes of breast cancer show different spatial
424 distributions of brain metastases," *PLoS One* **12**, e0188542 (2017).
- 425 26. N. Izutsu, M. Kinoshita, T. Ozaki, M. Sakai, K. Nakanishi, T. Nakayama, Y. Tamaki, and H. Kishima, "Cerebellar
426 preference of luminal a and b type and basal ganglial preference of *her2*-positive type breast cancer-derived brain
427 metastases," *Mol. Clin. Oncol.* **15**, 1–7 (2021).
- 428 27. S. Ali, A. Ismael, A. Mohammed, and H. Hefny, "An enhanced deep learning approach for brain cancer mri images
429 classification using residual networks," *Artif. Intell. Medicine* **102**, 101779 (2020).
- 430 28. G. C. Carter, M. Mohanty, K. Stenger, C. M. Guimaraes, S. Singuru, P. Basa, S. Singh, V. Tongbram, S. Kuemmel,
431 V. Guarneri *et al.*, "Prognostic factors in hormone receptor-positive/human epidermal growth factor receptor 2-negative
432 (*hr*+/*her2*-) advanced breast cancer: A systematic literature review," *Cancer Manag. Res.* **13**, 6537 (2021).
- 433 29. J. Neman, J. Termini, S. Wilczynski, N. Vaidehi, C. Choy, C. M. Kowolik, H. Li, A. C. Hambrecht, E. Roberts, and
434 R. Jandial, "Human breast cancer metastases to the brain display gabaergic properties in the neural niche," *Proc. Natl.*
435 *Acad. Sci.* **111**, 984–989 (2014).




Fig. 1. Schematic illustration of Gamma Knife radiosurgery (GKRS) stereotactic headset, intracranial metastasis (brown), and targeted radiation location in X (yellow), Y (Red) and Z (Green) planes. These coordinates are subsequently mapped to a traditional three dimensional cartesian plane (right), and repeated for all brain metastases for all patients undergoing GKRS at our institution.




Fig. 2. Scatter and kernel density plots showing the spatial distribution of metastatic brain tumors for all breast cancer patients in sagittal, axial, and coronal views. A) Scatter plot, sagittal view, red dot indicates the mean; B) Scatter plot, axial view, red dot indicates the mean; C) Scatter plot, coronal view, red dot indicates the mean; D) Kernel density plot, sagittal view. Color shading indicates density, closed dark regions indicate highest density of metastatic tumors. Distributions on top and right are probability distribution functions (pdf's) describing the distribution of tumors. E) Same as (D), axial view; F) Same as (D), coronal view.




Fig. 3. Kernel density plots of metastatic tumor distributions according to genetic subgroups, sagittal, axial, and coronal views. Color shading indicates density, closed dark regions indicate highest density of metastatic tumors. Distributions on top and right are probability distribution functions (pdf's) describing the distribution of tumors. A) Column showing ER-/PR-/Her2+ subgroup, three views; B) Column showing ER+/PR+/Her2- subgroup, three views; C) Column showing TNBC subgroup, three views; D) Column showing TPBC subgroup, three views.




Fig. 4. Scatter plot of all breast cancer metastatic brain tumors in X-Y-Z coordinates showing the Principal component axes PC1-PC2-PC3. A) 3D data representation in (X,Y,Z) space showing the orientation of (PC1,PC2,PC3). B) 2D projection onto (X,Y) plane; C) 2D projection onto (X,Z) plane; D) 2D projection onto (Y,Z) plane.




Fig. 5. Violin plots (probability distribution functions) of metastatic distributions according to molecular groupings (indicated by color), comparing distributions in original Cartesian X-Y-Z coordinates, and Principal component coordinates (PC1-PC2-PC3). MI metric is shown for each pair. A) Distribution along PC1-axis according to molecular grouping. Yellow dash indicates mean, white dot indicates median; B) Distribution along PC2-axis according to molecular grouping. Yellow dash indicates mean, white dot indicates median; C) Distribution along PC3-axis according to molecular grouping. Yellow dash indicates mean, white dot indicates median; D) Distribution along X-axis according to molecular grouping. Yellow dash indicates mean, white dot indicates median. We use this representation to arrange the subtypes from left to right in order of increasing divergence between the means and medians; E) Distribution along Y-axis according to molecular grouping. Yellow dash indicates mean, white dot indicates median; F) Distribution along Z-axis according to molecular grouping. Yellow dash indicates mean, white dot indicates median.




Fig. 6. Scatter plots of metastatic tumors, anterior/posterior, lateral/medial, three different views. A) Sagittal view, blue indicates anterior, pink indicates posterior, grey dots indicate washout region; B) Axial view, blue indicates anterior, pink indicates posterior, grey dots indicate washout region; C) Coronal view, blue indicates anterior, pink indicates posterior, grey dots indicate washout region; D) Sagittal view, blue indicates lateral, red indicates medial; E) Axial view, blue indicates lateral, red indicates medial; F) Coronal view, blue indicates lateral, red indicates medial; G) Topographical illustration (axial) showing the X-coordinates corresponding to the lateral and medial regions.




Fig. 7. Histograms (Count and Proportion) showing spatial distribution (anterior/posterior; lateral/medial) by molecular subtypes and groupings. A) Count per molecular subtype, anterior (blue), posterior (pink), watershed (grey); B) Count per molecular grouping, anterior (blue), posterior (pink), watershed (grey); C) Count per molecular subtype, lateral (blue), medial (red); D) Count per molecular grouping, lateral (blue), medial (red); E) Proportion per molecular subtype, anterior (blue), posterior (pink), watershed (grey); F) Proportion per molecular grouping, anterior (blue), posterior (pink), watershed (grey); G) Proportion per molecular subtype, lateral (blue), medial (red); H) Proportion per molecular grouping, lateral (blue), medial (red).




Fig. 8. Mutual information heat map for the six breast cancer molecular subtypes along PC1-axis. Low mutual information indicates the distributions associated with the two subtypes are not highly dependent. High mutual information indicates the distributions associated with the two subtypes are highly dependent.




Fig. S9. Scatter plots of metastatic tumor distributions according to genetic subgroups, sagittal, axial, and coronal views. Red dot indicates mean. A) Column showing ER-/PR-/Her2+ subgroup, three views; B) Column showing ER+/PR+/Her2- subgroup, three views; C) Column showing TNBC subgroup, three views; D) Column showing TPBC subgroup, three views.




Fig. S10. Violin plots (probability distribution functions) of metastatic distributions according to molecular subtype (indicated by color), comparing distributions in original Cartesian X-Y-Z coordinates, and Principal component coordinates (PC1-PC2-PC3). MI metric is shown for each pair. A) Distribution along PC1-axis according to molecular subtype. Yellow dash indicates mean, white dot indicates median; B) Distribution along PC2-axis according to subtype. Yellow dash indicates mean, white dot indicates median; C) Distribution along PC3-axis according to subtype. Yellow dash indicates mean, white dot indicates median; D) Distribution along X-axis according to molecular subtype. Yellow dash indicates mean, white dot indicates median. We use this representation to arrange the subtypes from left to right in order of increasing divergence between the means and medians; E) Distribution along Y-axis according to molecular subtype. Yellow dash indicates mean, white dot indicates median; F) Distribution along Z-axis according to molecular subtype. Yellow dash indicates mean, white dot indicates median.

ER	PR	Her2/Neu	No. Metastases	Anterior	Lateral	Median X	Median Y	Median Z	Median	Median	Median
				:	:						
				Posterior	:	Axis	Axis	Axis	PC1 Axis	PC2 Axis	PC3 Axis
				Watershed	Medial						
+			110	28:42:40	25:85	101.35	73.30	103.85	-3.13	0.12	2.98
-			116	31:56:29	21:95	99.90	76.30	103.60	-10.56	-1.05	2.80
	+		86	19:35:32	21:65	98.85	72.15	102.45	-3.42	-0.35	1.02
	-		124	32:57:35	23:101	99.90	76.30	103.85	-4.93	-1.13	1.64
		+	124	27:60:37	22:102	106.80	76.80	101.80	-2.56	-0.77	1.74
		-	91	23:37:31	25:66	98.70	72.70	104.20	-9.31	0.55	-0.33
+	+	+	20	4:8:8	3:17	110.25	69.35	114.30	-2.91	-1.08	-7.26
+	+	-	49	10:20:19	16:33	100.4	73.90	99.1	-3.98	1.19	-2.01
-	-	+	75	17:40:18	12:63	99.60	77.90	93.90	-9.56	0.28	2.25
-	-	-	28	8:11:9	7:21	103.45	66.20	107.15	-12.98	-0.58	-1.04
+	-	+	8								
-	+	+	4								
+	-	-	5								
-	+	-	2								

Table S1. Number of brain metastases and proportion of different spatial subgroupings along with the medians in Cartesian and Principal Component coordinates by tumor subtype. The last four molecular subgroupings (last four rows) are not considered in this paper due to the small number of data points.

	PC1	PC2	PC3	X	Y	Z
ER-PR-Her2+/ ER-PR-Her2-	8.966 ± 3.394	15.508 ± 3.330	16.350 ± 3.655	13.023 ± 3.466	15.548 ± 3.648	16.878 ± 3.600
ER+PR+Her2-/ ER-PR-Her2+	10.767 ± 3.443	17.467 ± 3.496	18.515 ± 3.801	15.805 ± 3.457	17.472 ± 3.694	15.132 ± 3.532
ER+PR+Her2+ / ER-PR-Her2+	10.979 ± 3.376	17.392 ± 3.667	21.222 ± 3.881	14.446 ± 3.645	17.146 ± 3.745	18.476 ± 3.658
ER+PR+Her2-/ ER-PR-Her2-	12.540 ± 3.527	15.359 ± 3.531	16.221 ± 3.548	14.470 ± 3.536	16.200 ± 3.607	14.571 ± 3.503
ER+PR+Her2+/ ER-PR-Her2-	12.614 ± 3.376	15.249 ± 3.606	18.921 ± 3.789	13.100 ± 3.613	16.029 ± 3.504	18.112 ± 3.677
ER+PR+Her2+ / ER+PR+Her2-	14.808 ± 3.589	17.018 ± 3.530	20.996 ± 3.820	16.014 ± 3.547	18.158 ± 3.645	16.247 ± 3.766
PR- / ER-	6.031 ± 3.238	17.394 ± 3.854	17.993 ± 3.653	12.273 ± 3.307	13.348 ± 3.636	17.442 ± 3.644
Her2+ / ER-	6.168 ± 3.172	19.844 ± 3.765	17.623 ± 3.609	12.571 ± 3.580	15.414 ± 3.530	17.102 ± 3.598
Her2+ / PR-	7.021 ± 3.326	18.185 ± 3.638	17.752 ± 3.664	11.999 ± 3.372	15.715 ± 3.678	17.683 ± 3.720
Her2- / ER-	8.184 ± 3.338	18.879 ± 3.704	17.836 ± 3.590	14.506 ± 3.569	16.038 ± 3.762	14.683 ± 3.501
PR+ / ER-	8.383 ± 3.290	20.139 ± 3.885	18.164 ± 3.536	15.609 ± 3.565	14.186 ± 3.436	15.196 ± 3.607
ER+ / ER-	8.469 ± 3.476	19.238 ± 3.652	17.926 ± 3.622	15.484 ± 3.515	15.438 ± 3.548	15.482 ± 3.679
Her2+ / Her2-	9.034 ± 3.363	19.914 ± 3.792	17.226 ± 3.539	14.204 ± 3.428	18.322 ± 3.758	14.884 ± 3.548
PR- / Her2-	9.164 ± 3.319	17.213 ± 3.469	17.709 ± 3.605	14.189 ± 3.423	15.927 ± 3.691	15.359 ± 3.520
Her2+ / PR+	9.227 ± 3.452	21.094 ± 3.730	18.118 ± 3.514	15.350 ± 3.506	16.584 ± 3.661	15.006 ± 3.450
PR+ / PR-	9.334 ± 3.323	18.487 ± 3.690	18.253 ± 3.550	15.325 ± 3.542	14.24 ± 3.522	15.662 ± 3.541
ER+ / PR-	9.393 ± 3.582	17.88 ± 3.851	18.09 ± 3.490	14.980 ± 3.571	15.482 ± 3.830	16.098 ± 3.715
Her2+ / ER+	9.447 ± 3.351	20.288 ± 3.861	17.830 ± 3.778	15.093 ± 3.558	17.836 ± 3.753	15.588 ± 3.586
PR+ / Her2-	11.178 ± 3.466	20.357 ± 3.804	17.978 ± 3.604	17.838 ± 3.564	16.798 ± 3.715	12.604 ± 3.338
ER+ / Her2-	11.516 ± 3.469	19.579 ± 3.714	17.827 ± 3.669	17.216 ± 3.831	18.183 ± 3.745	13.118 ± 3.396
ER+ / PR+	11.601 ± 3.455	20.712 ± 3.723	18.224 ± 3.532	18.455 ± 3.691	16.696 ± 3.625	13.286 ± 3.510

Table S2. Mutual Information. Ranked listing (from smallest to largest) of MI between pairs of molecular subtypes along each of the coordinate axes, using the PC1 coordinate axis values to order the list. Smaller MI values indicate weaker mutual dependence (i.e. more independence), larger MI values indicate stronger mutual dependence.